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The main (M) group of human immunodeficiency virus type 1 (HIV-1) is responsible for the global AIDS
epidemic while HIV-1 group O (outlier) and HIV type 2 are endemic only in west and central Africa. The failure
of HIV-2 and especially HIV-1 group O to spread following the initial zoonotic jumps is not well understood.
This study was designed to examine the relative replicative capacities between these human lentiviruses. A
pairwise competition experiment was performed with peripheral blood mononuclear cells with eight HIV-2
isolates, 6 group O viruses, and 15 group M viruses of subtype A (2 viruses), B (5 viruses), C (4 viruses), D (2
viruses) and CRF01_AE (2 viruses). HIV-1 group M isolates of any subtype were typically 100-fold-more fit
than group O or HIV-2 strains when competed in peripheral blood mononuclear cells from various humans.
This order in replicative fitness was also observed when virus pairs were added to human dendritic cells and
then cocultured with primary, quiescent T cells, which is the model for HIV-1 transmission. These results
suggest that reduced replicative and transmission fitness may be contributing to the low prevalence and limited
geographical spread of HIV-2 and group O HIV-1 in the human population.
Virulence is defined as the rate of host mortality as a con-
sequence of infection (30) but is commonly related to repro-
duction rate and pathogenic potential of the parasite (12).
When the size, density, and reproduction rates of the host
population are limiting, greater fitness of a parasite may be a
consequence of reduced virulence to ensure host and parasite
survival (2, 18). In contrast to acute infections by lethal viruses,
the relatively low virulence of the human immunodeficiency
virus (HIV) establishes a long chronic disease leading to AIDS
and mortality. The long life span of an infected host coupled
with efficient transmission has led to the spread of HIV to over
40 million people throughout the world. Early in the epidemic,
both type 1 HIV (HIV-1) and HIV-2 were prevalent but geo-
graphically separated in Africa (east and central versus west,
respectively) (60). Over the past 20 years, HIV-2 has nearly
faded as a human pathogen, whereas HIV-1 not only has
expanded throughout Africa but has founded new epidemics
throughout the world (60). This study has examined possible
phenotypic differences between diverse HIVs that are found
primarily in sub-saharan Africa.
HIV-1 and HIV-2 were introduced into the human popula-
tion through two separate but not necessarily isolated zoonotic
jumps. Close genetic relationships between the genomes of the
HIV types and simian immunodeficiency viruses (SIVs) sug-
gest that humans acquired this type 1 human lentivirus from
chimpanzees (Pan troglodytes) and HIV-2 from sooty manga-
beys (Cercocebus atys) (19). Appearance of the HIV-1 group
M, N, and O lineages may be due to divergent evolution in the
human population or separate cross-species transmission
events of diverse SIVcpz strains (19, 23, 52). Group O may
have evolved from a recombination event between SIVcpz
strains found in different subspecies of chimpanzees such as
Pan troglodytes troglodytes and Pan troglodytes schweinfurthii
(43). All of these cross-species transmission events appeared to
have originated in western Africa but only HIV-1 group M
founded the global pandemic, with an estimated introduction
date in the early 1930s (28, 29). Group M HIV-1 has subse-
quently diverged in the human epidemic and can now be sub-
classified into nine subtypes (A, B, C, D, F, G, H, J, and K) and
15 circulating recombinant forms (CRFs) (36, 44).
Prevalence of HIV-2 and group O, unlike that of HIV-1
group M, appears to have stabilized or actually decreased in
the human population over the past decade (4, 21). Group O,
which may have been responsible for 20% of the HIV-1 infec-
tions in the Republic of Cameroon, has now dropped to ap-
proximately 1% of HIV-1 cases or an estimated 0.4% preva-
lence (Fig. 1A) (4, 59). In contrast, HIV-2 appeared to
dominate over HIV-1 in western Africa during the early epi-
demic and peaked in the mid-1990s at a 10% prevalence in the
Senegalese population (Fig. 1A) (21). In all west African coun-
tries, HIV-2 has been rapidly displaced by HIV-1 but is still
frequently observed in dual infections with HIV-1 (39). The
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increasing prevalence of HIV-1 group M over HIV-2 or HIV-1
group O in the west African population has been attributed to
increased transmission of the former (21, 27).
Fitness is defined as an organism’s replicative capacity/
adaptability in a given environment (16). This definition sug-
gests that HIV-1 group M is more fit than HIV-2 or HIV-1
group O in the human population. However, the nature of this
multilayered environment introduces significant complexities
in measuring fitness of these HIV types/groups in human pop-
ulations. We have adopted a rigorous method to measure rel-
ative viral fitness ex vivo, which involves competitions between
two or more viral strains in tissue culture (16, 40). This system
was first developed to study fitness/evolution of various RNA
viruses (e.g., vesicular stomatitis virus) (16, 40, 41) and recently
applied to HIV-1 (61, 62). It was soon discovered that drug-
resistant mutations reduced HIV-1 replication efficiency (24,
34, 38, 47) and that ex vivo HIV-1 fitness was directly related
to disease progression (48, 57). From these studies, it appears
that HIV-1 fitness in different layered environments may be
interrelated but not necessarily consequential (3). For exam-
ple, the ability of virus to replicate in human peripheral blood
mononuclear cells (PBMCs), defined as ex vivo fitness (3, 48),
in tissue culture may be related to virus levels produced by
these same cells in the blood of an infected human host. How-
ever, other factors such as immune response and host genetics
will influence viral loads, undoubtedly play a role in shaping
HIV-1 evolution, and thus alter fitness during disease. None-
theless, it appears that HIV-1 fitness is one of the strongest
predictors of disease progression (6, 8, 9, 48).
The relationship between ex vivo HIV fitness and distribu-
tion of these isolates in the human population is definitely
more complex than the direct correlation between HIV-1 fit-
ness and rate of disease progression (3). Fitness of virus within
the human population is likely related to both efficiency and
opportunity for transmission. Opportunity is more a factor of
human behavior and mechanics of the transmission event,
whereas efficiency of transmission could be affected by virus
attributes. Since the rate of host cell entry appears to be the
dominant factor controlling ex vivo HIV-1 fitness (5, 32, 49), it
is possible that ex vivo fitness could be related to transmission
efficiency and ultimately virus distribution.
To date, there have been few studies examining the replica-
tion efficiencies of HIV groups/types (7, 54), and most of these
have not involved primary HIV-1 isolates infecting primary
FIG. 1. (A) Prevalence of HIV in sub-saharan Africa is summa-
rized in the grey panel. Sub-saharan Africa is further subdivided into
various regions based on group M subtype prevalence. The size of the
letters provides an indication of the prevalence of that subtype or CRF
in a given region. For example, northeastern countries of Africa (i.e.,
Ethiopia, Eritriea, and Somalia) are dominated by subtype C. The grey
shaded areas show the approximate range of HIV-2, HIV-1/HIV-2,
and HIV-1 group O in Africa. (B) Virus characteristics of the isolates
used in the dual infection/competition experiments. Most isolates have
the syncytium-inducing phenotype (as determined with MT-2 cell line)
and are able to use either the CXCR4 chemokine receptor exclusively
as entry coreceptor or are dualtropic for both CXCR4 and CCR5 (as
determined with a U87.CD4 cell line expressing either CXCR4 or
CCR5). One isolate, O13, was initially identified as an SI isolate but
was later found to be an NSI/R5 HIV-1 group O isolate through
phenotypic analyses (see Materials and Methods). (C) Analysis of
genotypic relationships of diverse HIV isolates by the neighbor-joining
method. Phylogenetic neighbor-joining trees were constructed from
alignments of the 400-nucleotide pol gene fragments from several HIV
reference strains and 22 HIV isolates employed in the subsequent
fitness analyses. Accession numbers for all pol gene fragments are
provided in Materials and Methods. ** and *, bootstrap resampling
values of 80 to 95% and95%, respectively. Branch lengths are drawn
to scale, and the scale bar represents 0.1 substitution per nucleotide.
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human CD4 cells, have not included group O isolates, and
finally have not performed head-to-head competitions. Thus,
this research field has not examined the possible relationships
between fitness of different HIV types/HIV-1 groups, their
distribution in the epidemic, and pathogenesis in the human
host. In this study, we performed almost 1,000 dual virus com-
petitions to find the winner of each competition and then
compared this phenotypic trait of relative HIV replication ca-
pacity to viral genetic diversity and distribution in the human
population.
MATERIALS AND METHODS
Cells. PBMCs were obtained from HIV-seronegative blood donors (two Cau-
casians and one Bantu African; one Caucasian for the dendritic cell [DC]/T-cell
competitions) by Ficoll-Hypaque density gradient centrifugation of heparin-
treated venous blood. Cells were stimulated with 2 g/ml phytohemagglutinin
(PHA; Gibco BRL) for 3 days and further maintained in RPMI containing 10%
fetal bovine serum (Cellgro), 10 mM HEPES, 1 ng/ml interleukin-2 (IL-2; Gibco
BRL), 100 U/ml penicillin (Cellgro), and 100 g/ml streptomycin (Cellgro).
Monocyte- and lymphocyte-enriched fractions were generated by counterflow
elutriation of 6  108 PBMCs (58). Monocytes were further purified by sheep
erythrocyte rosetting, yielding95% CD3/CD4 monocytes and0.5% T cells
(58). Addition of IL-4 (20 ng/ml) and granulocyte-macrophage colony-stimulat-
ing factor (20 ng/ml) to RPMI containing 10% fetal bovine serum, 100 U/ml
penicillin, and 100 g/ml streptomycin differentiated monocytes into interstitial-
type DCs (MO-DCs). Cell cultures were fed every 3 days and immunopheno-
typed (CD3/CD4, CD1a, CD13/CD14, and DC-SIGN; all from Becton
Dickinson) before use in infection experiments on day 7 (58). Frozen lymphocyte
fractions were thawed on the day of infection and used to isolate autologous
CD4 T cells.
Viruses. HIV-1 group M and group O isolates were obtained from the AIDS
Research and Reference Reagent Program, while the HIV-2 strains were pre-
viously isolated from patients attending the AIDS clinic at the Institute of
Tropical Medicine in Antwerp, Belgium. Virus stocks were propagated and
expanded in short-term cultures of PBMCs treated with PHA–IL-2. Twenty-nine
different primary HIV isolates (syncytium-inducing/CXCR4-tropic [SI/X4], du-
altropic [R5X4], or NSI/R5) were selected for this study (Fig. 1B). The tissue
culture dose for 50% infectivity was calculated by the Reed and Muench method
(33, 50). Briefly, each stock of HIV isolate was serially diluted in triplicate and
then plated with 105 PBMCs in a 96-well plate. Infectivity in each well was tested
by a radiolabeled reverse transcriptase (RT) assay as previously described (56).
It is important to note that the classic and not the virtual method was used for
the calculation of infectious titers (33).
Growth competition assays. Nearly 1,000 full pairwise dual infection/compe-
tition experiments were done with 15 HIV-1 group M, 6 HIV-1 group O, and 8
HIV-2 viruses (Fig. 1B). Dual infection/competition experiments were per-
formed with SI/X4 or dualtropic isolates in PBMCs from one donor (with the
same donor as for tissue culture dose for 50% infectivity determination and the
same blood draw) on 24-well cell culture plates and in duplicate. A subset of
competitions was repeated with PBMCs from two additional donors (one Cau-
casian and one Bantu African). Full pairwise competitions with eight NSI/R5
isolates (subtypes B and C, HIV-1 group O, and HIV-2; two isolates each) were
also performed with PHA/IL-2 PBMCs. Finally, the same NSI/R5 subtype B
isolates were used for pairwise comparison with two NSI/R5 group O and HIV-2
viruses in cocultures of MO-DC and autologous CD4 T cells. Cells were
infected with two viruses at equal multiplicity of infection (MOI), 0.0005 for
PBMCs and 0.001 for MO-DCs. A previous study (48) used a higher MOI for
dual infections (0.01 and 0.1), but we have recently observed that MOIs of0.01
saturated susceptible cell populations within two to three rounds of replication
and prevent further virus competitions (5; A. Abraha and E. J. Arts, unpublished
data). Interestingly, the relative fitness values did not vary for a dual MOI in the
range of 0.005 to 0.0005. Env PCR products could not be amplified from dual
virus competitions performed at an MOI of 0.0001. Uninfected cultures were
used as HIV-negative controls, and monoinfected cultures of each virus corre-
sponded to positive controls. Virus mixtures were incubated with 2 105 PBMCs
or 105 MO-DCs at 37°C in 5% CO2, washed three times with 1 phosphate-
buffered saline for 24 h and 6 h postinfection, respectively, and then resuspended
in complete medium. Subsequently, 3  105 autologous CD4 T cells were
added to the MO-DCs (1/3 ratio), and cultures were fed with complete medium
(without cytokines) twice a week. Cell-free supernatant was collected and as-
sayed for RT activity 3 and 6 days postinfection, as previously described (56).
Two aliquots of supernatants and cells were harvested at day 8 after infection and
stored at 80°C for subsequent analysis.
PCR strategy. For all dual-infected and monoinfected cultures, proviral DNA
was extracted from lysed PBMCs with the QIAamp DNA Blood kit (QIAGEN).
Isolated viral DNA was PCR amplified using a set of external primers, followed
by nested amplification. Both the external and nested PCRs were carried out in
a 100-l reaction mixture under defined cycling conditions (step 1, 94°C for 4
min; step 2, 94°C for 30 s, 55°C for 30 s, and 72°C for 45 s, repeated 35 times; step
3, final hold at 4°C). A different PCR strategy was adopted for either intragroup
competitions (group M/group M, group O/group O, and HIV-2/HIV-2) or in-
tergroup competitions (group M/group O, group O/HIV-2, and group M/HIV-2).
Intragroup competitions were PCR amplified in the C2V3 env region, while
intergroup competitions were amplified in the pol RT region due to extensive
intergroup sequence diversity in env. Primers utilized for these analyses are listed
in Table S1 in the supplemental material. Controls for the PCR and heterodu-
plex tracking assays (HTAs) are shown in Fig. 2 and Fig. S1 in the supplemental
material. A schematic representation of the PCR primers, products, HTA anal-
yses, and fitness calculations is provided in Fig. 3.
As described below, control PCR amplifications were performed using the
different pol primer pairs to amplify the group M/group O, group O/HIV-2, and
group M/HIV-2 competitions and different env primer pairs to amplify the group
M/group M, group O/group O, and HIV-2/HIV-2 competitions. Briefly, DNA
extracted from PBMCs monoinfected with the various HIV-1 group M and group
O and HIV-2 isolates was PCR amplified with the last five sets of primer pairs
listed in Table S1 in the supplemental material. Each set of primers was only
PCR amplified from the HIV isolates belonging to a specific group/type. This
DNA template was extracted from an agarose gel, purified, quantified by mea-
surement of optical density at 260 nm, and then diluted to 108 to 10 copies/l.
Each dilution of a specific HIV-1 group M and group O or HIV-2 template was
then PCR amplified with sets of both external and nested primer pairs designed
for the group M/group O, group M/HIV-2, and group O/HIV-2 competitions
(listed as M/O RTS1 W to O/HIV-2 RTA3 in Table S1 in the supplemental
material). The PCR products from these amplification controls were run on a 1%
agarose gel and then quantified using the ethidium bromide gel quantitation
feature of the Bio-Rad phosphorimager and Quantity One software.
HTA analysis of dual infections. Nested PCR products in env and pol RT were
analyzed by HTAs to determine the amount of virus production in the dual
infection/competition experiments (Fig. 3D) (48). Radiolabeled DNA probes
were PCR amplified from regions of env and pol RT using the same primer sets
described above (see Table S1 in the supplemental material). For this amplifi-
cation, one of the nested primers was radiolabeled with T4 polynucleotide kinase
(PNK; Gibco BRL) and 2 Ci of [-32P]ATP. Subsequently, radiolabeled PCR-
amplified probes were separated on 1% agarose gels and purified with the
QIAquick gel extraction kit (QIAGEN). The HTA reaction mixtures containing
DNA annealing buffer (100 mM NaCl, 10 mM Tris-HCl [pH 7.8], 2 mM EDTA),
10 l of amplified DNA from the competition culture, and 0.1 pmol of radioac-
tive probe DNA were denatured at 95°C for 3 min, followed by incubation at
37°C for 5 min and rapid transfer on wet ice to allow reannealing. The DNA
heteroduplexes were resolved on 6% nondenaturing polyacrylamide gels (29:1
30% acrylamide-bis) for 4 h at 200 V. Afterwards, gels were dried for 45 min at
80°C, exposed to X-ray film to make autoradiograms (Kodak MR film), subse-
quently exposed on a phosphorimaging screen, and scanned with a phosphorim-
ager (Personal Molecular Imager FX; Bio-Rad), followed by analysis using the
Quantity One software package from Bio-Rad.
For this study, it was necessary to see if the probes of the various groups and
types could efficiently anneal to PCR products of different types and groups for
accurate HTA quantitations of dual infections. The external products from the
control PCR amplifications (see above) were mixed for mock dual-infection
analyses by HTA. The external PCR products were mixed at 10 pg:1 pg, 10:10,
and 1:10 ratios for the following pairs: group M plus group O, group M plus
HIV-2, and group O plus HIV-2. These mixtures were then PCR amplified using
the appropriate set of nested primers (see Table S1 in the supplemental mate-
rial). Ten microliters of this amplified mixture and 1 pmol of radiolabeled probe
(of the various groups and types) were then added to an HTA reaction mixture.
One or two probes representing an isolate of each group/type were used in these
mock competitions. The heteroduplexes from this mock competition and from
mock monoinfections (10 pg of DNA added to the nested PCR and then an-
nealed to the probe) were resolved on a 6% polyacrylamide gel (PAG) and
quantified on a Bio-Rad phosphorimager screen.
Estimation of viral fitness. In the dual infection/competition experiments, the
final ratio of two viruses produced in a dual infection was estimated by hetero-
duplex tracking analysis and compared to the production in monoinfections (48).
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Production of individual HIV isolates in a dual infection (fo) was divided by the
initial proportion in the inoculum (io). This is referred to as relative fitness (W 
fo/io), while the ratio of the relative fitness values of each HIV variant in the
competition is a measure of the fitness difference (WD) or ratio between two HIV
strains (WD WM/WL), with WM and WL corresponding to the relative fitness of
the more- and less-fit virus, respectively (Fig. 3C).
Sequence analyses. A segment of the HIV-1 env gene (C2-V3; 336 nucleo-
tides) and of the pol gene (polymerase region of RT; 600 nucleotides) was PCR
amplified using an external set and then a nested set of primers (see Table S1 in
the supplemental material; the first six sets of primer pairs). This PCR product
was then purified and sequenced in the sense and antisense directions with a
nested set of primers. All sequencing reactions were performed using the ABI
Prism Big Dye Terminator Cycle Sequencing Ready Reaction kit (Perkin-Elmer)
and an ABI 377 sequencer at the University of California—Davis Sequencing
Facility. The chromatogram files were read using the Chromas 1.6 program
(Helensvale, Australia). The C2-V3 env and RT sequences were aligned with the
CLUSTAL X program, version 1.64b (55). Neighbor-joining phylogenetic trees
including reference env sequences were constructed using CLUSTAL X and then
drawn with Treeview 1.6.1 (Fig. 1C) (42). Bootstrap resampling (1,000 data sets)
of multiple alignments was performed to test the statistical robustness of the
trees. Kimura two-parameter distances were calculated with the DNADIST
program in the PHYLIP package (51).
Nucleotide sequence accession numbers. The following accession numbers
refer to the sequences of the HIV isolates employed in this study. The DNA
sequence of HIV-1 env C2-V3 and RT regions determined as part of this study
has been submitted to GenBank, but accession numbers are not yet available
(indicated by the abbreviation SNA, for submitted but not available). The pol
sequences available from GenBank are as follows: isolate name 92UG029 (A8),
accession number DQ067920; A15UG (A14), DQ067921; 92US076 (B4),
DQ067914; 92BR014 (B12), AF458232; NL4-3, M19921 (full genome); TCDD22
(C22), DQ067916; TCDD28 (C25), DQ067917; 92UG021 (D1), AF009396;
93UG067 (D4), DQ067915; CMU06 (E6), DQ067918; CMU02 (E7), DQ067919;
BCF02 (O2), Y14497; BCF03 (O3), Y14498; BCF06 (O11), Y14499; BCF07
(O12), Y14500; BCF011, DQ067913; V1390 (H2-2), DQ067922; CBL20 (H2-3),
DQ067924; C185 (H2-4), DQ067926; C1197 (H2-5), DQ067923; V1884 (H2-6),
DQ067927; V11437 (H2-9), DQ067925.
RESULTS
Testing the PCR and HTA system. In this study, we com-
pared the relative replicative fitness of viral isolates classified
as HIV-1 group M and group O and HIV-2. Accurate mea-
surement of dual virus production is dependent on conserva-
tion of primer binding sites on both HIV DNAs in a dual
infection. This will ensure unbiased PCR amplifications. PCR
products from dual infections were added together with a ra-
diolabeled probe (i.e., PCR product amplified from another
HIV isolate), denatured, annealed, and run on a nondenatur-
ing polyacrylamide gel. Increased annealing on the HIV-1
DNA probe to one HIV DNA compared to the other from a
dual infection can be corrected based on annealing efficiency to
HIV DNA from a monoinfection (48). Nonetheless, it is im-
portant to verify efficient annealing and detection by HTA. In
the first control experiment, we tested PCR amplification ef-
ficiency using primer sets specific for the pol gene to measure
dual virus production in the intergroup M/intergroup O, group
M/HIV-2, and group O/HIV-2 competitions. Primers for the
pol gene were selected due to the higher sequence homology
between HIV types and groups than was observed with the env
gene, which was amplified for HTA and dual-virus detection in
the intragroup/intratype competitions. DNA extracted from
PBMCs monoinfected with the various HIV-1 group M and
group O and HIV-2 isolates was PCR amplified with group- or
type-specific primer pairs (the last five sets in Table S1 in the
supplemental material). These env or pol DNA products were
then purified, quantified, and diluted to 108 to 10 copies/l for
use in a nested PCR amplification with primer pairs specific for
the intra- (pol gene) and inter- (env gene) type/group DNA
(see Table S1 in the supplemental material). As shown in the
supplementary figures, all nested primer pairs amplified the
HIV env or pol DNA of different groups and types with nearly
equal efficiency. Slight variations in amplification efficiency
were not statistically significant.
Upon PCR amplification of both HIV DNAs in a dual in-
fection, it was important to ensure that the PCR-amplified
probe (either env or pol DNA of HIV isolates different from
that used in the competitions) was annealing to both PCR
products. We previously confirmed that the HTA results were
identical if carried out with PCR-amplified DNA of DNA
extracted from infected PBMC cultures or RT-PCR-amplified
DNA of RNA extracted from virus released from these cul-
tures (48). It was also shown that the radiolabeled PCR probes
generated from the HIV-1 group M env gene did not signifi-
cantly differ in annealing of the two group M HIV-1 DNA
products from a dual infection. Any variation in annealing was
compensated for by dividing the intensity of DNA heterodu-
plex of specific virus from competition by the intensity of that
heteroduplex from a monoinfection (Fig. 2). It was, however,
necessary to confirm that the latter observations with intra-
group M analyses (5, 48) held true for HTA analyses of com-
petitions using highly divergent HIV isolates of group M and
group O and type 2. The external PCR products from quanti-
tation study described in the figure in the supplemental mate-
rial were mixed for mock PCR amplication-HTA analyses.
HTAs were then performed with two probes representing an
isolate of each group/type used in these mock competitions.
The heteroduplexes from this mock competition and from
mock monoinfections (10 pg of PCR DNA product annealed
to the probe) were resolved on a polyacrylamide gel and quan-
tified by phosphorimaging (Fig. 2A). The raw intensity of each
heteroduplex band in a mock competition between group O3
and group M C25 viral DNA was plotted in Fig. 2B.
Differential annealing efficiencies to the PCR products of all
HIV DNAs (of group M and group O and HIV-2 isolates) was
evident and dependent on relative sequence homology be-
tween probe and target DNA products. Since equal amounts of
env PCR product were used for all HTA analyses (mono and
dual), intensities of these heteroduplex bands were adjusted
based on the intensity of the heteroduplex in the mock
monoinfections (Fig. 2A). Based on this adjustment, the rela-
tive intensities of the O3 and C25 heteroduplexes were equal
to the original proportion of viral DNA added to the mock
dual infections (Fig. 2B), which was subject to the same PCR
amplifications and HTA analyses. Similar mock analyses were
performed on pairwise mock competitions involving the D1,
C25, O2, O3, O11, H2-2, and H2-3 templates. In each mock
competition, the ratio of DNA detected by HTA was similar to
input ratios. Slight variations (15%) in the input to output
ratios for all mock intra- and inter- group/type competitions
are likely due to the standard errors in spectrophotometry
readings of the input template DNA. These variations would
not arise in HTA analyses of the actual dual infections.
Dual virus competitions to compare fitness of HIV groups
and types. Nearly 1,000 dual virus competitions in human
PBMCs and in dendritic cell/T-cell cocultures were performed,
using 15 HIV-1 group M isolates (2 from each of subtypes A,
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D, and CRF01_AE; 5 of subtype B strains; and 4 of subtype C)
(Fig. 1B), 6 HIV-1 group O isolates, and 8 HIV-2 isolates.
Twenty HIV strains were obtained from patients in late disease
(i.e., CD4 cell counts typically300/ml) are syncytium induc-
ing (SI)/X4 tropic or dualtropic as indicated by their ability to
infect CD4 U87 cells expressing either CXCR4 or CCR5. Fig.
S2 in the supplemental material shows the coreceptor usage of
HIV-1 group M and group O isolates. All coreceptor usage
assays were performed with the same viral stocks used for
competitions but prior to the determination of infectious titers.
Thus, replication kinetics from these monoinfections were per-
formed with an arbitrary amount of virus (100 l) and cannot
be compared to relative fitness values. Assays for coreceptor
usage by HIV-2 isolates were performed on different dates and
by monitoring virus production by capsid p24 release and not
by RT activity (data not shown). Nine HIV isolates were iso-
lated from patients with asymptomatic disease and were strictly
nonsyncytium-inducing (NSI) and CCR5 tropic (R5) (Fig. 1B).
Every possible combination of NSI/R5 or SI/X4 virus pairs
were added to PHA-treated, IL-2-stimulated PBMCs at equal
multiplicities of infection (0.0005 infectious particles per cell)
(Fig. 3A). Virus production in the cell cultures was initially
measured by a radioactive reverse transcriptase assay (48).
Both supernatant and cells were harvested at peak viremia in
the culture.
Viral DNA was then PCR amplified from cell extracts and
employed in heteroduplex tracking assays to measure dual
virus production. This technique was modified from the previ-
ous descriptions (48), due to sequence variation between HIV
groups and types. For all intragroup or intratype competitions,
the diverse C2-V3 region of the env gene was PCR amplified
(Fig. 3B), then annealed to a radiolabeled env C2-V3 DNA
probe, and resolved on a nondenaturing polyacrylamide gel
(Fig. 3D). In contrast, the higher sequence diversity between
groups and types required the amplification of the more con-
served region of RT using specific primer sets for M/HIV-2,
M/O, and HIV-2/O competitions (Fig. 3B; see Table S1 in the
supplemental material). Equal PCR amplification of all HIV
strains by the designated primer sets and relative annealing to
the probes in the HTA was compared and/or analyzed as
described above (Fig. 2). All relative fitness values were de-
rived from a set of dual infections (e.g., M versus O isolates) by
performing HTAs with at least two probes (e.g., group M and
O RT probes) (data not shown). As indicated in Fig. 3D, many
of the primary HIV-1 isolates were viral swarms and as a result
were identified as multiple heteroduplexes in the HTA (e.g.,
virus H2-1 and H2-4). Relative fitness and fitness difference
values were calculated as shown in Fig. 3C. Finally, the esti-
mated frequency of recombination between HIV-1 isolates in
FIG. 2. Testing for preferential probe annealing in the heterodu-
plex tracking. The heteroduplex tracking assay is used to detect the
PCR products originating from the two HIV isolates added to dual
infections. The external PCR products from quantitation study de-
scribed in Fig. S1 in the supplemental material were mixed for mock
PCR amplication-HTA analyses. Several pairs of group M plus group
O, group M plus HIV-2, and group O plus HIV-2 PCR products were
mixed at 10:1, 10:10, and 1:10 ratios and then PCR amplified using the
appropriate set of nested primers. Ten microliters of this amplified
mixture was then added with 1 pmol of radiolabeled probe to an HTA
reaction mixture (see Materials and Methods). The heteroduplexes
from this mock competition and from mock monoinfections (10 pg of
DNA added to the nested PCR and then annealed to the probe) were
resolved on a 6% PAG and quantified on a Bio-Rad phosphorimager
screen. (A) Image of a 6% PAG containing an HTA of the mock
competition between O3 and C25 HIV-1 DNA, which was then probed
with a group M HXB2 probe. (B) The raw intensity of each
heteroduplex band in this mock HTA was plotted. (C) The intensity of
each heteroduplex band was then plotted relative to the heteroduplex
of only the PCR amplified DNA from mock monoinfections. It is
important to note that each lane of the HTA shown in panel A
contains the same amount of PCR-amplified DNA. The HTA shown in
panel A and the analyses shown in panels B and C were repeated with
the same samples using the group O isolate ESP1 probe. Similar mock
analyses were performed on pairwise mock competitions involving
HTAs, following nested amplification of the D1, C25, O2, O3, O11,
H2-2, and H2-3 templates (data not shown).
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dual infections and/or competitions was0.1% per 1,000 bp or
well below the limit of HTA detection (48). Fig. 4 displays all
of the fitness difference values derived from competitions be-
tween the designated HIV isolate and each of the other HIV-1
group M and O and HIV-2 strains, whereas the mean relative
fitness values for intra- or inter- group/type competitions are
shown in Fig. 5A to C. Duplicate competitions were performed
with the same PBMCs at the same time. Only a subset of these
repeat competitions was analyzed (n  50). As previously
reported (5, 48), relative fitness values varied 10% in dupli-
cate dual infections performed with the same PBMC sample
(data not shown).
HIV-1 group M isolates are more fit than group O or HIV-2.
Competitions in PBMC clearly revealed that HIV-1 group M
was more fit than HIV-2 or group O isolates. All competitions
involved HIV-1 pairs of the same phenotype (i.e., NSI/R5 or
SI/X4) (Fig. 4A and C), since the SI/X4 or dualtropic viruses
typically outcompeted the NSI/R5 HIV isolates (data not
shown). Eleven SI/X4 HIV-1 isolates (representing five of the
most prevalent HIV-1 group M subtypes: A, B, C, D, and
CRF01 _AE), 5 group O isolates, and 6 HIV-2 isolates had
similar mean relative fitness values in intragroup/intratype
pairwise competitions (see bars labeled group M, group O, and
HIV-2 in Fig. 5A, B, and C, respectively). The mean relative
fitness value (W) from all group M virus competitions was
equal to 1.01 (	 0.717 or range of fitness values from 83
competitions) (P 0.79) (Fig. 5A). These mean relative fitness
values did not include the NSI/R5 viruses of these groups, but
their intragroup/intratype fitness also resulted in equal fitness.
This does not imply that some isolates within a group or type
are not more or less fit, but differences in intragroup fitness
were less dramatic than that observed between types and
groups. For example, subtype D viruses D1 and D4 were the
most fit of the other group M SI/X4 isolates and had the
highest mean relative fitness values (derived from competitions
against the other group M isolates) (Fig. 5A). Even within a
subtype, fitness could vary. The subtype A SI/X4 isolate A8 had
a mean relative fitness among group M competitions of 1.41 (	
0.329; 10 competition), which was significantly greater than
that of 0.915 (	 0.810; 10 competition) for A14 (P  0.02)
(Fig. 5A). In the intratype-2 competitions, only H2-3 proved to
be more fit than other HIV-2 strains (P  0.01). Group M
subtype C isolates of both SI/X4 (C22 and C25) or NSI/R5 (C8
and C9) phenotypes were less fit than any group M isolate of
the same phenotype (Fig. 5A). As previously reported, the
NSI/R5 subtype C isolates, C8 and C9, were outcompeted by
the subtype B isolates, B2 and B10, in PBMCs (Fig. 4C).
Although intragroup or intratype-2 competitions revealed
FIG. 3. Schematic representation and sample results of HIV competition experiments, heteroduplex tracking assays, and fitness analyses.
(A) Virus was added alone or in pairs to PHA-stimulated and IL-2-treated PBMCs at an equal MOI of 0.0005. Cells were washed after 24 h to
remove residual virus. Cells and virus supernatant were harvested at day 10 and lysed for subsequent DNA extraction. (B) Extracted DNA from
dual infections was PCR amplified using env primer pairs specific for HIV-1 M, HIV-1 O, and HIV-2 (see Table S1 in the supplemental material).
RT primers were also designed to amplify DNA from HIV-1 M/O, HIV-1 O/HIV-2, and HIV-1 M/HIV-2 dual infections (see Table S1 in the
supplemental material). (C) Relative fitness values (W) and a fitness ratio referred to as fitness difference (WD) were derived as shown. (D) Samples
of HTAs and fitness calculations for HIV-1 group M versus HIV-2 competitions, as well as intragroup M and intratype HIV-2 competitions.
Radiolabeled, PCR-amplified DNA from viruses A8, D1, and H2-2 were used as probes.
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similar mean relative fitness values (Fig. 3D), a definite rank
order between these types and groups emerged from the full
pairwise competitions involving SI/X4 and NSI/R5 viruses in
PBMCs (Fig. 4 and 5). Almost without exception, group M
HIV-1 isolates outcompeted HIV-1 group O strains by 100-
fold in direct competitions (Fig. 4). The outgrowth of SI/X4
HIV-2 isolates in PBMC cultures coinfected with the group O
strains was less dramatic but convincing nonetheless, consid-
ering that not a single HIV-2 isolate lost a competition against
a group O strain (Fig. 4A and C). The two group O NSI/R5
isolates were also less fit but could compete to a minimal extent
with group M and HIV-2 NSI/R5 isolates, as indicated by mean
relative fitness values (Fig. 5A and C). However, aside from
the NSI/R5 O2 outcompeting the HIV-2 VI1905 (Fig. 4C), the
NSI/R5 group O isolates lost all of the competition against
HIV-2 and group M isolates. Even the group M subtype C
isolates (SI/X4 C22 and C25 or NSI/R5 C8 and C9), consider-
ably less fit than any other group M isolate of the same phe-
notype, could outcompete most HIV-1 group O and many
HIV-2 strains in competitions (Fig. 4A and C and 5D). Head-
to-head competitions in PBMC between HIV-1 group M and
HIV-2 isolates in PBMC cultures indicated that the HIV-1
group M strains were the victors in 27 of 38 competitions. In
comparison to the larger set of SI/X4 competition results, there
FIG. 5. (A to C) The mean relative fitness values (maximum, 2) for intratype/intragroup and intertype/intergroup competitions in PBMC
involving both SI and NSI HIV-1 group M and group O and HIV-2 primary isolates. (D) Intertype/intergroup versus intratype/intragroup mean
relative fitness of all SI isolates. Fitness differences were derived from competitions involving HIV-1 M and O and HIV-2 are shown in Fig. 4.
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was a slight increase in NSI/R5 group O mean relative fitness
when competed against NSI/R5 group M or HIV-2 strains.
The relationship between intra- and inter- type/group fitness
derived from400 competitions is presented in Fig. 5D. In this
chart, mean relative fitness of each HIV isolate derived from
competitions against all others in the same group or type (in-
tratype/intragroup fitness) is plotted on the y axis, whereas the
x axis represents the mean relative fitness of each isolate com-
peted against all isolates from the different type and groups
(intertype/intergroup fitness). From these analyses, it is clear
that the order of relative fitness is HIV-1 group M  group
M-subtype C  HIV-2  HIV-1 group O (Fig. 5D).
Host PBMC effect on HIV-1 fitness. Fitness dominance of
HIV-1 group M over HIV-1 group O and, to a lesser extent,
HIV-2 was confirmed with PBMCs of different human do-
nors and genetic backgrounds (Fig. 4B and 6). A subset of
the pairwise HIV competitions was repeated in PBMCs de-
rived from other HIV-negative donors of different human
races (two Caucasians and one Bantu African) (Fig. 6, bars
1 to 3). As observed in previous studies (5, 48), the relative
fitness values did not significantly differ in dual virus com-
petitions performed with PBMC cultures of different human
donors. It is important to note that these fitness values
represent the production of each HIV-1 isolate relative to
the other in a competition and do not represent total virus
production, which can differ by 100 fold (data not shown).
Figure 4C provides all of the fitness difference values for
these subset competitions in different donor PBMCs. It is
important to note that for two competitions (A14 versus
O11 and A14 versus C25), the WD values were lower in
donor 2 PBMCs than in PBMCs from donors 1 and 3 (for
A14/O11, donor 2 values were 2.17, compared to donors 1
and 3 values of 100; donor 2, 2.29; donor 1, 100; donor 3,
6.92). At this time, we have no explanations for these dis-
crepancies. However, there was no reversal in the winner of
these competitions. Consistencies in the relative fitness of
primary HIV-1 isolates regardless of donor PBMCs have
also been described in several other studies (5, 48, 57).
Measuring replicative fitness of different HIV types and
groups in a transmission model. HIV fitness in PBMCs is
correlative to disease progression within a host (termed patho-
genic fitness) (6, 8, 9, 48), but the relationship to spread in the
human population is tenuous. Certainly, the lower HIV-2 fit-
ness reflects reduced HIV-2 virulence or pathogenicity in vivo
(i.e., the longer time to develop AIDS) (21, 27, 31, 35). Little
is still known about pathogenesis or rate of disease progression
among individuals infected with group O virus (26, 46, 59).
However, increased prevalence of HIV-1 group M over HIV-2
and group O in western Africa (Fig. 1) may be related more to
transmission efficiency than pathogenesis in the host. Models
of sexual transmission suggest that DCs may be the initial
targets of primary infection (10, 11, 15, 45, 53, 58). HIV-1 can
then be transferred to CD4 T cells or monocytes in the blood
from the infected DCs or from DCs that trapped the virus
through adhesion by DC-SIGN (Fig. 7A) (20, 58). To examine
if pathogenic fitness of group M and O and HIV-2 isolates was
related to transmission fitness, we competed six pairs of
NSI/R5 viruses in dendritic cell–T-cell cultures. Blood from a
fourth Caucasian donor was used to purify/differentiate inter-
stitial-type dendritic cells (MO-DCs) from primary human
monocytes using IL-4 and granulocyte-macrophage colony-
stimulating factor and then immunophenotyped (CD3/
CD4, CD1a, CD13/CD14, and DC-SIGN) prior to in-
fection experiments. Following a 6-h incubation with the
HIV-1 pairs, MO-DCs were washed and then cultured with
autologous, unstimulated CD4 T cells. HTA was then per-
formed at day 8 to determine the relative levels of dual virus
production. In all cases, increased fitness of HIV-1 group M
over HIV-2 and group O isolates was even more pronounced
in the MO-DC–T-cell cultures than in the PHA- and IL-2-
treated PBMC cultures (Fig. 7B). These results suggest that
the transfer of HIV-1 group O or HIV-2 by DC to T cells is 10-
to 100-fold-less efficient than that observed with group M
strains. Increased replication of HIV-1 group M isolates over
group O or HIV-2 strains suggests that this MO-DC T-cell
model can support various levels of infections by diverse
strains. We and others have previously shown that DC (or
Langerhans cell [LC]) infections and/or virus transfer to T cells
did not significantly differ among HIV-1 isolates of different
group M subtypes (5, 15, 45). Thus, it is plausible to suggest
that HIV-2 and group O viruses have lower transmission fit-
ness in vitro than group M when considering that this transfer/
infection could play a major role in primary infection.
DISCUSSION
HIV-1 group O and HIV-2 have never established epidemics
in the human population to the extent that HIV-1 group M
has. Findings of this study and others support the hypothesis
that the differential spread of HIV-1 group M and group O and
HIV-2 in the human population (i.e., in vivo fitness) may be
FIG. 6. Comparing the relative fitness of various primary HIV isolates in a subset of competitions performed with PBMCs of three different
HIV-negative blood donors (two Caucasians and one Bantu African). Mean relative fitness values (maximum, 2) are shown for two intragroup/
intratype and three intergroup/intertype competitions in the three different blood donors. A full set of relative fitness values is shown in Fig. 4B.
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related to the differential replicative capacities in PBMCs and
in MO-DC plus T-cell cultures (M  HIV-2  O), as well as
differences in transmission (13, 22) and pathogenicity (M 
HIV-2  O?) (21, 25, 27, 31, 35, 59). Data presented herein
suggest that group O isolates are at least 100-fold-less fit than
all HIV-2 isolates and group M isolates, including subtype C
strains, and that most HIV-2 isolates are significantly less fit
(100 fold) than group M HIV-1 isolates. Thus, it is conceiv-
able that this extremely low replicative capacity in comparison
with that of HIV-1 group M strains has led to decreased group
O and HIV-2 transmission. Similarly, the lower HIV-2 fitness
reflects reduced HIV-2 virulence or pathogenicity in vivo (i.e.,
the longer time to develop AIDS) (21, 27, 31, 35). Little is still
known about pathogenesis or rate of disease progression
among individuals infected with group O virus (26, 46, 59).
At the time of introduction into the human species (1920s to
1930s) (28, 29), group M and group O viruses may have com-
peted for the same susceptible population in central Africa,
specifically Cameroon (Fig. 1A). Several HIV surveillance
studies and molecular clock analyses suggest that reduced
group O and HIV-2 prevalence is not due simply to more
recent zoonotic introductions (28, 29, 43). Aside from founder
effects and socioepidemiological factors, significant differences
in fitness between group M and O viruses could have shaped
the epidemic, giving advantage to the fitter group M viruses.
Moreover, differences in pathogenicity and rate of transmis-
sion between HIV-1 group M and HIV-2 (21, 22, 26, 27, 31, 35,
46, 59) may be a direct consequence of or compounded by the
poor replicative capacity of HIV-2 in both PBMCs and MO-
DC T-cell cultures. In west African countries where repeated
cross-sectional data are available, the prevalence and incidence
of HIV-2 have been declining, while HIV-1 group M preva-
lence in the same populations has increased (21). The mathe-
matical model of Anderson and May suggests that in a popu-
lation where both viruses are being transmitted sexually,
HIV-1 group M will competitively displace HIV-2 in the long
FIG. 7. (A) Schematic representation of the HIV dual infection of the MO-DC–CD4 T-cell cultures. MO-DCs were first exposed to a pair
of HIV isolates for 6 h, after which free virus was washed away and CD4 T cells were added. The prevailing theory suggests that MO-DC can
mediate T-cell stimulation and transfer of virus. CD4 T cells are either infected through trans exposure from virus produced from infected
MO-DCs or presented in cis via DC-SIGN-mediated endocytosis and release. (B) Fitness difference values derived from pairwise competitions with
NSI/R5 HIV-1 M and O and HIV-2 primary isolates in PBMCs and MO-DCs plus CD4 T-cell cocultures.
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run (1). Our data support their model in that HIV-2 is less fit
than HIV-1 group M subtypes.
Within the HIV-1 group M epidemic, subtype C has in-
creased in prevalence over the past 10 years to become the
predominant clade in Africa and Asia (17). Both NSI/R5 and
SI/X4 subtype C HIV-1 isolates were significantly less fit in
PBMC competitions than all other group M isolates of the
same phenotype (5). However, subtype C strains were still at
least 100-fold-more fit than HIV-1 group O isolates and could
compete with HIV-2 isolates. We suspect that the key to sub-
type C survival and rapid expansion in the epidemic as opposed
to low and isolated prevalence of HIV-2 and HIV-1 group O to
western Africa may be related to efficiency of transmission (5,
13, 14, 22, 37). As described, HIV-1 fitness within a human
population could be related to both transmission fitness, re-
lated in part to replication capacity of a virus in dendritic
Langerhans cells (5, 58), and pathogenic fitness, related to
replication efficiency in primary CD4 T lymphocytes or
PBMCs (5, 48). In the case of HIV-1 group O and HIV-2, the
extreme reduction in replication efficiency was observed in
both pathogenic and transmission fitness. However, group M
subtype C HIV-1 isolates had modest reductions in pathogenic
fitness compared to all other group M isolates and still out-
competed nearly all group O and HIV-2 strains in PBMCs. In
skin-derived LCs (5), subtype B and C HIV-1 isolates had
similar fitness values. Although primary LCs are not com-
pletely analogous to the MO-DC cultures for the measurement
of in vitro transmission fitness, these results imply that the
reduced subtype C fitness was not sufficient to overcome virus
trapping by this dendritic cell lineage. Thus, the poor relative
replication efficiency of subtype C in PBMCs may be related to
slower disease progression, longer survival of the human host,
and thus more time for transmission (5, 48). Higher fitness of
subtype C in skin-derived LCs compared to PBMC cultures
may also suggest efficient transmission (5). Other studies with
chimpanzees as a model for human infection suggest that sub-
type C isolates may actually have a transmission advantage
over other group M strains (5, 14, 37). In contrast, several
studies suggest that sexual transmission efficiency of HIV-2
may be significantly less than that of HIV-1 (13, 22). The
expansion of HIV-1 group M and contraction of the HIV-2
and group O epidemics in Africa are currently being modelled,
based on this in vitro pathogenic/transmission fitness data and
in vivo epidemiological studies (D. Hollingsworth, E. J. Arts,
and R. M. Anderson, unpublished data).
In conclusion, we have established the relative order of fit-
ness among different HIV groups and types: HIV-1 group M
HIV-2  HIV-1 group O. This order in replicative and trans-
mission fitness is nearly a perfect match to the order of prev-
alence in the human epidemic. Current modelling studies of
these findings may help to explain the limited spread of HIV-1
group O and HIV-2, as well as the continued dominance of
HIV-1 group M throughout the world but especially in west
Africa.
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